This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Study offers hope of new treatment for rheumatoid arthritis

Patients who do not respond to current rheumatoid arthritis (RA) treatments may benefit from a new form of treatment that has been shown in a study to be effective against symptoms of the disease.

The RA-BEAM study is the first to demonstrate that the drug baricitinib is more effective in improving the symptoms of rheumatoid arthritis than the current standard treatment of injectable biologic anti-TNF medications. Baricitinib has been specifically developed as a treatment for rheumatoid arthritis.

A common and potentially debilitating disease, rheumatoid arthritis typically affects multiple joints and causes pain, swelling and stiffness that can greatly affect a person’s quality of life.

For the full story on University of Oxford website